Quest Diagnostics (DGX) EPS (Weighted Average and Diluted) (2009 - 2026)

Quest Diagnostics has disclosed EPS (Weighted Average and Diluted) across 18 years of filings, most recently posting $2.24 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at $2.24, up 15.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.05 (up 14.41% YoY), and the FY2025 annual result was $8.75, up 13.78% from the prior year.
• EPS (Weighted Average and Diluted) came in at $2.24 for Q1 2026 at Quest Diagnostics, up from $2.18 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.92 in Q1 2022 to a low of $0.92 in Q4 2022.
• The 5-year median for EPS (Weighted Average and Diluted) is $1.99 (2024), against an average of $2.01.
• Across the five-year window, EPS (Weighted Average and Diluted) tumbled 70.7% in 2022 and jumped 84.78% in 2023, its largest moves.
• Quest Diagnostics' EPS (Weighted Average and Diluted) stood at $0.92 in 2022, then soared by 84.78% to $1.7 in 2023, then rose by 14.71% to $1.95 in 2024, then grew by 11.79% to $2.18 in 2025, then rose by 2.75% to $2.24 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $2.24 (Q1 2026), $2.18 (Q4 2025), and $2.16 (Q3 2025), per Business Quant data.